Child ObesityNCT03870984
Efficacy of Nuts in Obese Children.
A study testing wNUTS, low-caloric diet plus nuts and w/oNUTS, low-caloric diet without nuts in people with Child Obesity, run by Universita di Verona at 1 site in Italy.
Trial summary
Obesity is a problem of ever-growing importance, especially in industrialized countries, both in adults and in the pediatric population. Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop metabolic syndrome and atherosclerotic disease, pathophysiological… Read more about this study
- Who is it for?
- Ages 6 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Child Obesity
- What is being tested?
- wNUTS, low-caloric diet plus nuts and w/oNUTS, low-caloric diet without nuts
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteItaly
- Study dates
- 19 Mar 2019to 18 May 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- obese subjects (BMI ≥ 95th percentile for age and sex; reference tables for WHO BMI);
- Aged between 6 and 17 years;
- Signature applied in the informed consent by both parents and consent of the child
Who cannot join
- chronic liver diseases (hepatitis, cirrhosis).
- Chronic renal failure (serum creatinine> 1.2 mg / dL).
- Malignancies.
- Diabetes (fasting blood glucose ≥ 126 mg / dl or therapy with oral hypoglycemic drugs or insulin).
- cholesterol-lowering or antihypertensive terapy.
- Notes allergies to nuts or hazelnuts or food intolerance to nuts and/or hazelnuts.
- Treatment of less than 6 weeks with any medication which can interfere with fecal microbiota (particularly antibiotics or laxatives).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy of Walnuts and Hazelnuts on the Modification of the Lipid Content of Erythrocyte Membranes in Obese Children. A Randomised Controlled Trial.
Obesity is a problem of ever-growing importance, especially in industrialized countries, both in adults and in the pediatric population. Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop metabolic syndrome and atherosclerotic disease, pathophysiological basis of cardiovascular events. Alteration of the elastic properties of the arteries has been described previously in obese children and adolescents and is considered an initial marker of atherosclerotic vascular damage. The determination of the indices of arterial stiffness (PWV, Pulse Wave Velocity; AI, Augmentation Index, SI, Stiffness Index) is possible through techniques currently used for the determination of vascular function even in children.
Nuts and hazelnuts are rich in potentially beneficial substances including unsaturated fatty acids, especially omega-6 (present in both) and omega-3 (present only in nuts), Several clinical trials have already shown in adults a potential beneficial effect of the addition of different types of nuts (walnuts, hazelnuts, cashews, pistachios, etc.) on the characteristics of the metabolic syndrome also through their possible antioxidant effect and vasoactive. In children, some epidemiological studies have associated with a higher consumption of nuts reduced risk of hypertension, dyslipidemia, obesity and fasting glucose. The study will be conducted with a randomized design with two arms in parallel with blinded operator. The main objective of this study is to assess the efficacy of 15 grams of nuts and 15 grams of nuts a day in addition to a low calorie diet on the content of erythrocyte membranes of alpha-linolenic acid three months after the beginning of the trial in a group of obese children. Secondary objectives are to evaluate the efficacy of walnuts and hazelnuts in improving the systolic and/or diastolic blood pressure values, lipid profile, glucose and fasting insulin, vascular function.
Read the detailed description
Obesity is a problem of ever-growing importance, especially in industrialized countries, widespread both in adults and in the pediatric population.
Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop high blood pressure, insulin resistance, diabetes, hyperlipidemia, fatty liver disease and the resulting long-term complications. This cluster of metabolic and hemodynamic risk factors, which is known as metabolic syndrome, greatly increases the risk of cardiovascular events in adults. Cardiovascular disease is the leading cause of mortality and morbidity in developed countries and are becoming even in developing countries. Atherosclerotic disease is the pathophysiological basis of cardiovascular events. Atherosclerosis is a multifactorial disease whose early stages of subclinical damage are documented much earlier in cardiovascular events with non-invasive tests. The determination of the indices of arterial stiffness (PWV, Pulse Wave Velocity; AI, Augmentation Index, SI, Stiffness Index) is possible through techniques currently used for the determination of vascular function even in children. The alteration of the elastic properties of the arteries has been described previously in obese children and adolescents and is considered initial marker atherosclerotic vascular damage. Fats particularly saturated fats, without adequate intake of polyunsaturated fat, may facilitate the development of obesity.
The consumption of some specific foods including dried fruit (in a broad sense including walnuts, hazelnuts, almonds, cashews, etc.) within a reduced calorie diet is considered to be a promising approach in the prevention and care of the different components of the metabolic syndrome. The nuts and hazelnuts are rich in potentially beneficial substances including unsaturated fatty acids, especially omega-6 (present in both) and omega-3 (present only in nuts), L-arginine, fiber, minerals, vitamin E, fitosetrols and polyphenols.
Several clinical trials have already shown in adults a potential beneficial effect of the addition of different types of nuts (walnuts, hazelnuts, cashews, pistachios, etc.) on the characteristics of the metabolic syndrome also through their possible antioxidant and vasoactive effect .
In children, some epidemiological studies have associated a higher consumption of nuts with reduced risk of hypertension, dyslipidemia, obesity and fasting glucose alteration.
Our group conducted a study in obese children observing an inverse relationship between omega-6 polyunsaturated fatty acids, contained in large amounts in walnuts, and certain features of metabolic syndrome, such as waist circumference, triglycerides, fasting insulin, systolic blood pressure of 24-hours, suggesting a possible beneficial effect. The project was financed by health ministry and included also the present Protocol ("Obesity, hypertension and subclinical vascular damage in children: the role of dietary factors and lipid mediators. An epidemiological and translational study. "Project Code: GR-2011-02349630).
From arachidonic acid, the main omega-6 type polyunsaturated fatty acids (PUFA), certain metabolites are produced via cytochrome P450 which have vasoactive and natriuretic effect: 20-Hydroxyeicosatetraenoic acid (20-HETE), the epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs). From numerous studies in animal models and some human studies, it is known that these metabolites via cytochrome P450 may be involved both in the homeostasis of blood pressure pressure and in the development of hypertension. In particular, plasmatic 20-HETE has a vasoconstrictor effect while EETs are vasodilators; both exert renal natriuretic effect. Our study intends to verify if in a group of obese children, a low-calorie diet that contains a portion of walnuts and hazelnuts, can change the content of polyunsaturated fatty acids in erythrocyte membranes, particularly alpha-linolenic acid. This could result in possible beneficial effects on the characteristics of the metabolic syndrome in obese children, like an improvement of waist circumference, blood pressure, HDL cholesterol, triglycerides and blood sugar. Our study also intends to acquire information on the effect of the addition of walnuts and hazelnuts and the metabolites of polyunsaturated fatty acids omega-3 and omega-6 metabolized by cytochrome P450 that derives from these nuts in change vessel elasticity.
- STUDY DESIGN The study will be conducted with a randomized design (two arms in parallel with blinded operator). Doctors in charge of vascular measurements and laboratory technicians will not know which of the two groups analyzed will only have taken the low-calorie diet and who will have assumed the low-calorie diet with walnuts and hazelnuts.
- PURPOSE OF THE STUDY
The main objective of this study is to assess the efficacy of 15 grams of nuts and 15 grams of nuts a day in addition to a low calorie diet, in modifying the content of of alpha-linolenic acid in erythrocyte membranes evalutated three months after the beginning of the assumption in a group of obese children.
Secondary objectives are:
To evaluate the efficacy of walnuts and hazelnuts in improving in obese children:
- the systolic and/or diastolic blood pressure values;
- metabolic disorders (in particular of the lipid profile: LDL, HDL, triglycerides, and glucose: glucose and fasting insulin);
- vascular function measured by tonometry (PWV and PWA), and ultrasonography (carotid distensibility).
- the modifications of the profile of eicosanoids via CYP450 in plasma and urine
To evaluate:
- the relationship between intake of nuts and hazelnuts, fatty acid profile of erythrocyte membranes and eicosanoids via CYP450, the components of the metabolic syndrome including the blood pressure and vascular elasticity.
- Conditions
- Child Obesity
- Being tested
- wNUTS, low-caloric diet plus nuts, w/oNUTS, low-caloric diet without nuts
- Keywords
- obesity, children, nuts,
- Medical subject headings
- Pediatric Obesity, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
wNUTS, low-caloric diet plus nutsDietary supplement
15g of nuts and 15g of hazelnuts in association with low caloric diet
w/oNUTS, low-caloric diet without nutsOther
low caloric diet
| Study group | Role | What they receive |
|---|---|---|
| wNUTS, low-caloric diet plus nuts | Experimental | low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months. Receives: Dietary Supplement: wNUTS, low-caloric diet plus nuts; Other: w/oNUTS, low-caloric diet without nuts |
| w/oNUTS, low-caloric diet without nuts | Other | low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months. Receives: Other: w/oNUTS, low-caloric diet without nuts |
What is being measured
The primary outcome is the main question the study is designed to answer.
ALA change
Primary outcome is to compare percentage of fatty acids in erythrocyte membranes (in particular alpha-linolenic acid, ALA) with the content of other membrane-bound fatty acids. It will be compared in the two groups the ALA delta (delta%) between measurement at baseline compared to post-treatment (ie, after 3 months of treatment).
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
Secondary outcomes (19)
LA change
to compare percentage of fatty acids in erythrocyte membranes (in particular linoleic acid, LA) with the content of other membrane-bound fatty acids. It will be compared in the two groups the ALA delta (delta%) between measurement at baseline compared to post-treatment (ie, after 3 months of treatment).
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
ABPM change
To compare ambulatory blood pressure (mmHg) measured by validated devices (A\&D TM-2430; in the week preceding the beginning of the assumption of diet plus or minus nuts/hazelnuts) and after 3 months from randomization in the two arms.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
OFFICE BLOOD PRESSURE change
To compare mean arterial pressure obtained during the medical examination (mmHg) by oscillometric validated device in children (Omron 705 IT; average of three measurements) prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
HDL-cholesterol change
To compare HDL-cholesterol
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
triglycerides change
To compare triglycerides
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
glucose change
To compare plasma glucose
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
WAIST CIRCUMFERENCE change
To compare waist circumference change in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
WEIGHT change
To compare weight change in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
PWA (Augmentation Index; AIx) change
To compare AIx change as measured by pulse wave analysis (PWA) by SphygmoCor XCEL and in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
cfPWV change
To compare carotid femoral pulse wave velocity (PWV) change measured by tonometer (SphygmoCor XCEL) in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
carotid distensibility (cDC) change
To compare cDC change measured by ultrasound in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma EETs change
To compare plasma epoxyeicosatrienoic acids, metabolites of arachidonic acid vis CYP450
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma DHETs change
To compare plasma dihydroxyeicosatrienoic acids, metabolites of EETs via sEH
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
urine DHETs change
To compare urine dihydroxyeicosatrienoic acids, metabolites of EETs via sEH
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma 20-HETE change
To compare plasma 20-hydroxyeicosatetraenoic acids, metabolites of arachidonic acid via CYP450
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
urine 20-HETE change
To compare urine 20-hydroxyeicosatetraenoic acids, metabolites of arachidonic acid via CYP450
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma EEQs change
To compare plasma epoxyeicosatetraenoic acids, metabolites of eicosapentaenoic acid via CYP450
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma EDPs change
To compare plasma epoxydocosapentaenoic acids, metabolites of docosahexaenoic acid via CYP450
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
MICROBIOTA change
To compare profile of the faecal microbiota by metagenomic of the gene sequences coding for the 16S rRNA prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.
Measured: baseline compared to post-treatment (ie, after 3 months of treatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2019
- Study start19 Mar 2019
- Primary completion18 May 2022
- Study completion18 May 2022
Why it stopped: Lack of recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Child ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized design. Two arms in parallel with blinded operator.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universita di Verona
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cristiano Fava, Universita di Verona
- Investigators
- Cristiano Fava, professor, Principal investigator, Universita di Verona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03870984
- Sponsor's protocol ID
- VRINoci
- Status last verified
- May 2022
- First submitted
- 6 Mar 2019
- Last updated
- 25 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Walnuts and Hazelnuts on the Modification of the Lipid Content of Erythrocyte Membranes in Obese Children. A Randomised Controlled Trial.
- ClinicalTrials.gov ID
- NCT03870984
- Acronym / sponsor ID
- VRINoci
- Conditions
- Child Obesity
- Keywords
- obesity, children, nuts,
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Lack of recruitment
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Universita di VeronaUniversity, hospital or other
- Study start
- 19 Mar 2019 (actual)
- Primary completion
- 18 May 2022 (actual)
- Study completion
- 18 May 2022 (actual)
- First posted
- 12 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is a problem of ever-growing importance, especially in industrialized countries, both in adults and in the pediatric population. Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop metabolic syndrome and atherosclerotic disease, pathophysiological basis of cardiovascular events. Alteration of the elastic properties of the arteries has been described previously in obese children and adolescents and is considered an initial marker of atherosclerotic vascular damage. The determination of the indices of arterial stiffness (PWV, Pulse Wave Velocity; AI, Augmentation Index, SI, Stiffness Index) is possible through techniques currently used for the determination of vascular function even in children.
Nuts and hazelnuts are rich in potentially beneficial substances including unsaturated fatty acids, especially omega-6 (present in both) and omega-3 (present only in nuts), Several clinical trials have already shown in adults a potential beneficial effect of the addition of different types of nuts (walnuts, hazelnuts, cashews, pistachios, etc.) on the characteristics of the metabolic syndrome also through their possible antioxidant effect and vasoactive. In children, some epidemiological studies have associated with a higher consumption of nuts reduced risk of hypertension, dyslipidemia, obesity and fasting glucose. The study will be conducted with a randomized design with two arms in parallel with blinded operator. The main objective of this study is to assess the efficacy of 15 grams of nuts and 15 grams of nuts a day in addition to a low calorie diet on the content of erythrocyte membranes of alpha-linolenic acid three months after the beginning of the trial in a group of obese children. Secondary objectives are to evaluate the efficacy of walnuts and hazelnuts in improving the systolic and/or diastolic blood pressure values, lipid profile, glucose and fasting insulin, vascular function.
Detailed description
Obesity is a problem of ever-growing importance, especially in industrialized countries, widespread both in adults and in the pediatric population.
Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop high blood pressure, insulin resistance, diabetes, hyperlipidemia, fatty liver disease and the resulting long-term complications. This cluster of metabolic and hemodynamic risk factors, which is known as metabolic syndrome, greatly increases the risk of cardiovascular events in adults. Cardiovascular disease is the leading cause of mortality and morbidity in developed countries and are becoming even in developing countries. Atherosclerotic disease is the pathophysiological basis of cardiovascular events. Atherosclerosis is a multifactorial disease whose early stages of subclinical damage are documented much earlier in cardiovascular events with non-invasive tests. The determination of the indices of arterial stiffness (PWV, Pulse Wave Velocity; AI, Augmentation Index, SI, Stiffness Index) is possible through techniques currently used for the determination of vascular function even in children. The alteration of the elastic properties of the arteries has been described previously in obese children and adolescents and is considered initial marker atherosclerotic vascular damage. Fats particularly saturated fats, without adequate intake of polyunsaturated fat, may facilitate the development of obesity.
The consumption of some specific foods including dried fruit (in a broad sense including walnuts, hazelnuts, almonds, cashews, etc.) within a reduced calorie diet is considered to be a promising approach in the prevention and care of the different components of the metabolic syndrome. The nuts and hazelnuts are rich in potentially beneficial substances including unsaturated fatty acids, especially omega-6 (present in both) and omega-3 (present only in nuts), L-arginine, fiber, minerals, vitamin E, fitosetrols and polyphenols.
Several clinical trials have already shown in adults a potential beneficial effect of the addition of different types of nuts (walnuts, hazelnuts, cashews, pistachios, etc.) on the characteristics of the metabolic syndrome also through their possible antioxidant and vasoactive effect .
In children, some epidemiological studies have associated a higher consumption of nuts with reduced risk of hypertension, dyslipidemia, obesity and fasting glucose alteration.
Our group conducted a study in obese children observing an inverse relationship between omega-6 polyunsaturated fatty acids, contained in large amounts in walnuts, and certain features of metabolic syndrome, such as waist circumference, triglycerides, fasting insulin, systolic blood pressure of 24-hours, suggesting a possible beneficial effect. The project was financed by health ministry and included also the present Protocol ("Obesity, hypertension and subclinical vascular damage in children: the role of dietary factors and lipid mediators. An epidemiological and translational study. "Project Code: GR-2011-02349630).
From arachidonic acid, the main omega-6 type polyunsaturated fatty acids (PUFA), certain metabolites are produced via cytochrome P450 which have vasoactive and natriuretic effect: 20-Hydroxyeicosatetraenoic acid (20-HETE), the epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs). From numerous studies in animal models and some human studies, it is known that these metabolites via cytochrome P450 may be involved both in the homeostasis of blood pressure pressure and in the development of hypertension. In particular, plasmatic 20-HETE has a vasoconstrictor effect while EETs are vasodilators; both exert renal natriuretic effect. Our study intends to verify if in a group of obese children, a low-calorie diet that contains a portion of walnuts and hazelnuts, can change the content of polyunsaturated fatty acids in erythrocyte membranes, particularly alpha-linolenic acid. This could result in possible beneficial effects on the characteristics of the metabolic syndrome in obese children, like an improvement of waist circumference, blood pressure, HDL cholesterol, triglycerides and blood sugar. Our study also intends to acquire information on the effect of the addition of walnuts and hazelnuts and the metabolites of polyunsaturated fatty acids omega-3 and omega-6 metabolized by cytochrome P450 that derives from these nuts in change vessel elasticity.
- STUDY DESIGN The study will be conducted with a randomized design (two arms in parallel with blinded operator). Doctors in charge of vascular measurements and laboratory technicians will not know which of the two groups analyzed will only have taken the low-calorie diet and who will have assumed the low-calorie diet with walnuts and hazelnuts.
- PURPOSE OF THE STUDY
The main objective of this study is to assess the efficacy of 15 grams of nuts and 15 grams of nuts a day in addition to a low calorie diet, in modifying the content of of alpha-linolenic acid in erythrocyte membranes evalutated three months after the beginning of the assumption in a group of obese children.
Secondary objectives are:
To evaluate the efficacy of walnuts and hazelnuts in improving in obese children:
- the systolic and/or diastolic blood pressure values;
- metabolic disorders (in particular of the lipid profile: LDL, HDL, triglycerides, and glucose: glucose and fasting insulin);
- vascular function measured by tonometry (PWV and PWA), and ultrasonography (carotid distensibility).
- the modifications of the profile of eicosanoids via CYP450 in plasma and urine
To evaluate:
- the relationship between intake of nuts and hazelnuts, fatty acid profile of erythrocyte membranes and eicosanoids via CYP450, the components of the metabolic syndrome including the blood pressure and vascular elasticity.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- Randomized design. Two arms in parallel with blinded operator.
| Arm | Type | Receives |
|---|---|---|
| wNUTS, low-caloric diet plus nuts | Experimental | Dietary Supplement: wNUTS, low-caloric diet plus nuts, Other: w/oNUTS, low-caloric diet without nutslow-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months. |
| w/oNUTS, low-caloric diet without nuts | Other | Other: w/oNUTS, low-caloric diet without nutslow-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months. |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- obese subjects (BMI ≥ 95th percentile for age and sex; reference tables for WHO BMI);
- Aged between 6 and 17 years;
- Signature applied in the informed consent by both parents and consent of the child
Key exclusion criteria (7 listed)
- chronic liver diseases (hepatitis, cirrhosis).
- Chronic renal failure (serum creatinine> 1.2 mg / dL).
- Malignancies.
- Diabetes (fasting blood glucose ≥ 126 mg / dl or therapy with oral hypoglycemic drugs or insulin).
- cholesterol-lowering or antihypertensive terapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| wNUTS, low-caloric diet plus nuts15g of nuts and 15g of hazelnuts in association with low caloric diet | Dietary supplement | wNUTS, low-caloric diet plus nuts |
| w/oNUTS, low-caloric diet without nutslow caloric diet | Other | w/oNUTS, low-caloric diet without nuts, wNUTS, low-caloric diet plus nuts |
Primary outcome
ALA change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
Primary outcome is to compare percentage of fatty acids in erythrocyte membranes (in particular alpha-linolenic acid, ALA) with the content of other membrane-bound fatty acids. It will be compared in the two groups the ALA delta (delta%) between measurement at baseline compared to post-treatment (ie, after 3 months of treatment).
19 secondary outcomes
LA change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
ABPM change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
OFFICE BLOOD PRESSURE change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
HDL-cholesterol change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
triglycerides change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
glucose change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
WAIST CIRCUMFERENCE change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
WEIGHT change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
PWA (Augmentation Index; AIx) change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
cfPWV change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
carotid distensibility (cDC) change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma EETs change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma DHETs change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
urine DHETs change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma 20-HETE change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
urine 20-HETE change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma EEQs change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
plasma EDPs change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
MICROBIOTA change
Time frame: baseline compared to post-treatment (ie, after 3 months of treatment)
Results and safety
The study was stopped early (reason given: Lack of recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2022.
Related trials for Child Obesity
Not yet recruiting
Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents
Binge Eating Disorder, Binge Eating
RecruitingPhase 3
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Obesity
Recruiting
National Childhood Obesity Prevention Programme BE FIT 24
Childhood Obesity
RecruitingPhase 2
Oxytocin for Weight Loss in Adolescents
Obesity, Adolescent, Oxytocin
Active, not recruitingObservational study
Guangzhou Preterm and Term Birth Cohort Study
Preterm Birth, Neurodevelopmental Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cristiano Fava, professor principal investigator
Universita di Verona
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing wNUTS, low-caloric diet plus nuts and w/oNUTS, low-caloric diet without nuts in people with Child Obesity, run by Universita di Verona at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 25 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Lack of recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ALA change (time frame: baseline compared to post-treatment (ie, after 3 months of treatment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2022.